15 June 2022 - Shionogi recognises the UK’s leadership role in introducing the world’s first fully ‘delinked’ pilot reimbursement model; pull incentives like this are an important step in making the market for novel antibiotics more predictable and sustainable.

Shionogi today announced that Shionogi B.V. had signed an agreement with NHS England to begin an innovative subscription payment model reimbursement of cefiderocol in England. In this model, companies are paid a fixed sum for antimicrobials based on a health technology assessment of their value to the NHS, rather than the volumes used.

Read Shionogi press release